IRIS Accounts Production v25.4.12.37 01413300 Board of Directors Board of Directors 1.4.24 31.3.25 31.3.25 Medium entities true true false true true false false false true false These accounts have been prepared in accordance with the provisions applicable to companies subject to the medium-sized companies regime. Fair value model Ordinary "A" 1.00000 Ordinary 1.00000 iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 01413300 2024-03-31 01413300 2025-03-31 01413300 2024-04-01 2025-03-31 01413300 2023-03-31 01413300 2023-04-01 2024-03-31 01413300 2024-03-31 01413300 ns15:EnglandWales 2024-04-01 2025-03-31 01413300 ns14:PoundSterling 2024-04-01 2025-03-31 01413300 ns10:Director1 2024-04-01 2025-03-31 01413300 ns10:Director2 2024-04-01 2025-03-31 01413300 ns10:CompanySecretary1 2024-04-01 2025-03-31 01413300 ns10:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 01413300 ns10:MediumEntities 2024-04-01 2025-03-31 01413300 ns10:Audited 2024-04-01 2025-03-31 01413300 ns10:Medium-sizedCompaniesRegimeForDirectorsReport 2024-04-01 2025-03-31 01413300 ns10:Medium-sizedCompaniesRegimeForAccounts 2024-04-01 2025-03-31 01413300 ns10:FullAccounts 2024-04-01 2025-03-31 01413300 1 2024-04-01 2025-03-31 01413300 ns10:OrdinaryShareClass1 2024-04-01 2025-03-31 01413300 ns10:OrdinaryShareClass2 2024-04-01 2025-03-31 01413300 ns10:Director3 2024-04-01 2025-03-31 01413300 ns10:Director4 2024-04-01 2025-03-31 01413300 ns10:RegisteredOffice 2024-04-01 2025-03-31 01413300 ns5:CurrentFinancialInstruments 2025-03-31 01413300 ns5:CurrentFinancialInstruments 2024-03-31 01413300 ns5:Non-currentFinancialInstruments 2025-03-31 01413300 ns5:Non-currentFinancialInstruments 2024-03-31 01413300 ns5:ShareCapital 2025-03-31 01413300 ns5:ShareCapital 2024-03-31 01413300 ns5:RevaluationReserve 2025-03-31 01413300 ns5:RevaluationReserve 2024-03-31 01413300 ns5:RetainedEarningsAccumulatedLosses 2025-03-31 01413300 ns5:RetainedEarningsAccumulatedLosses 2024-03-31 01413300 ns5:ShareCapital 2023-03-31 01413300 ns5:RetainedEarningsAccumulatedLosses 2023-03-31 01413300 ns5:RevaluationReserve 2023-03-31 01413300 ns5:RetainedEarningsAccumulatedLosses 2023-04-01 2024-03-31 01413300 ns5:RevaluationReserve 2023-04-01 2024-03-31 01413300 ns5:RetainedEarningsAccumulatedLosses 2024-04-01 2025-03-31 01413300 ns5:RevaluationReserve 2024-04-01 2025-03-31 01413300 1 2024-04-01 2025-03-31 01413300 1 2023-04-01 2024-03-31 01413300 2 2024-04-01 2025-03-31 01413300 2 2023-04-01 2024-03-31 01413300 ns5:NetGoodwill 2024-04-01 2025-03-31 01413300 ns5:IntangibleAssetsOtherThanGoodwill 2024-04-01 2025-03-31 01413300 ns5:LandBuildings ns5:OwnedOrFreeholdAssets 2024-04-01 2025-03-31 01413300 ns5:LeaseholdImprovements 2024-04-01 2025-03-31 01413300 ns5:PlantMachinery 2024-04-01 2025-03-31 01413300 ns5:FurnitureFittings 2024-04-01 2025-03-31 01413300 ns5:MotorVehicles 2024-04-01 2025-03-31 01413300 ns15:UnitedKingdom 2024-04-01 2025-03-31 01413300 ns15:UnitedKingdom 2023-04-01 2024-03-31 01413300 ns5:TotalGeographicSegmentsIncludingAnyUnallocatedAmount 2024-04-01 2025-03-31 01413300 ns5:TotalGeographicSegmentsIncludingAnyUnallocatedAmount 2023-04-01 2024-03-31 01413300 ns10:HighestPaidDirector 2024-04-01 2025-03-31 01413300 ns10:HighestPaidDirector 2023-04-01 2024-03-31 01413300 ns5:PlantEquipmentOtherAssetsUnderOperatingLeases 2024-04-01 2025-03-31 01413300 ns5:PlantEquipmentOtherAssetsUnderOperatingLeases 2023-04-01 2024-03-31 01413300 ns5:OwnedAssets 2024-04-01 2025-03-31 01413300 ns5:OwnedAssets 2023-04-01 2024-03-31 01413300 ns5:LeasedAssets 2024-04-01 2025-03-31 01413300 ns5:LeasedAssets 2023-04-01 2024-03-31 01413300 ns5:NetGoodwill 2023-04-01 2024-03-31 01413300 4 2024-04-01 2025-03-31 01413300 4 2023-04-01 2024-03-31 01413300 6 2024-04-01 2025-03-31 01413300 6 2023-04-01 2024-03-31 01413300 7 2024-04-01 2025-03-31 01413300 7 2023-04-01 2024-03-31 01413300 ns5:HirePurchaseContracts 2024-04-01 2025-03-31 01413300 ns5:HirePurchaseContracts 2023-04-01 2024-03-31 01413300 ns10:OrdinaryShareClass1 2023-04-01 2024-03-31 01413300 ns5:NetGoodwill 2024-03-31 01413300 ns5:NetGoodwill 2025-03-31 01413300 ns5:NetGoodwill 2024-03-31 01413300 ns5:LandBuildings 2024-03-31 01413300 ns5:LeaseholdImprovements 2024-03-31 01413300 ns5:PlantMachinery 2024-03-31 01413300 ns5:LandBuildings 2024-04-01 2025-03-31 01413300 ns5:LandBuildings 2025-03-31 01413300 ns5:LeaseholdImprovements 2025-03-31 01413300 ns5:PlantMachinery 2025-03-31 01413300 ns5:LandBuildings 2024-03-31 01413300 ns5:LeaseholdImprovements 2024-03-31 01413300 ns5:PlantMachinery 2024-03-31 01413300 ns5:FurnitureFittings 2024-03-31 01413300 ns5:MotorVehicles 2024-03-31 01413300 ns5:FurnitureFittings 2025-03-31 01413300 ns5:MotorVehicles 2025-03-31 01413300 ns5:FurnitureFittings 2024-03-31 01413300 ns5:MotorVehicles 2024-03-31 01413300 ns5:LeaseholdImprovements ns5:LeasedAssetsHeldAsLessee 2024-03-31 01413300 ns5:PlantMachinery ns5:LeasedAssetsHeldAsLessee 2024-03-31 01413300 ns5:MotorVehicles ns5:LeasedAssetsHeldAsLessee 2024-03-31 01413300 ns5:LeasedAssetsHeldAsLessee 2024-03-31 01413300 ns5:LeaseholdImprovements ns5:LeasedAssetsHeldAsLessee 2024-04-01 2025-03-31 01413300 ns5:PlantMachinery ns5:LeasedAssetsHeldAsLessee 2024-04-01 2025-03-31 01413300 ns5:MotorVehicles ns5:LeasedAssetsHeldAsLessee 2024-04-01 2025-03-31 01413300 ns5:LeasedAssetsHeldAsLessee 2024-04-01 2025-03-31 01413300 ns5:LeaseholdImprovements ns5:LeasedAssetsHeldAsLessee 2025-03-31 01413300 ns5:PlantMachinery ns5:LeasedAssetsHeldAsLessee 2025-03-31 01413300 ns5:MotorVehicles ns5:LeasedAssetsHeldAsLessee 2025-03-31 01413300 ns5:LeasedAssetsHeldAsLessee 2025-03-31 01413300 ns5:LeaseholdImprovements ns5:LeasedAssetsHeldAsLessee 2024-03-31 01413300 ns5:PlantMachinery ns5:LeasedAssetsHeldAsLessee 2024-03-31 01413300 ns5:MotorVehicles ns5:LeasedAssetsHeldAsLessee 2024-03-31 01413300 ns5:LeasedAssetsHeldAsLessee 2024-03-31 01413300 ns5:UnlistedNon-exchangeTraded ns5:CostValuation 2024-03-31 01413300 ns5:UnlistedNon-exchangeTraded 2025-03-31 01413300 ns5:UnlistedNon-exchangeTraded 2024-03-31 01413300 ns5:Subsidiary1 2024-04-01 2025-03-31 01413300 1 ns5:Subsidiary1 2024-04-01 2025-03-31 01413300 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2025-03-31 01413300 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2024-03-31 01413300 ns5:BetweenOneTwoYears ns5:Non-currentFinancialInstruments 2025-03-31 01413300 ns5:BetweenOneTwoYears ns5:Non-currentFinancialInstruments 2024-03-31 01413300 ns5:Non-currentFinancialInstruments ns5:BetweenTwoFiveYears 2025-03-31 01413300 ns5:Non-currentFinancialInstruments ns5:BetweenTwoFiveYears 2024-03-31 01413300 ns5:WithinOneYear ns5:CurrentFinancialInstruments ns5:HirePurchaseContracts 2025-03-31 01413300 ns5:WithinOneYear ns5:CurrentFinancialInstruments ns5:HirePurchaseContracts 2024-03-31 01413300 ns5:BetweenOneFiveYears ns5:HirePurchaseContracts 2025-03-31 01413300 ns5:BetweenOneFiveYears ns5:HirePurchaseContracts 2024-03-31 01413300 ns5:HirePurchaseContracts 2025-03-31 01413300 ns5:HirePurchaseContracts 2024-03-31 01413300 ns5:WithinOneYear 2025-03-31 01413300 ns5:WithinOneYear 2024-03-31 01413300 ns5:BetweenOneFiveYears 2025-03-31 01413300 ns5:BetweenOneFiveYears 2024-03-31 01413300 ns5:MoreThanFiveYears 2025-03-31 01413300 ns5:MoreThanFiveYears 2024-03-31 01413300 ns5:AllPeriods 2025-03-31 01413300 ns5:AllPeriods 2024-03-31 01413300 ns5:Secured 2025-03-31 01413300 ns5:Secured 2024-03-31 01413300 ns5:DeferredTaxation 2024-03-31 01413300 ns5:DeferredTaxation 2024-04-01 2025-03-31 01413300 ns5:DeferredTaxation 2025-03-31 01413300 ns10:OrdinaryShareClass1 2025-03-31 01413300 ns10:OrdinaryShareClass2 2025-03-31 01413300 ns5:RetainedEarningsAccumulatedLosses 2024-03-31 01413300 ns5:RevaluationReserve 2024-03-31 01413300 ns10:Director2 2 2024-03-31 01413300 ns10:Director2 2 2023-03-31 01413300 ns10:Director2 2 2024-04-01 2025-03-31 01413300 ns10:Director2 2 2023-04-01 2024-03-31 01413300 ns10:Director2 2 2025-03-31 01413300 ns10:Director2 2 2024-03-31 01413300 ns5:EntitiesWithJointControlOrSignificantInfluenceOverReportingEntity 2024-04-01 2025-03-31 01413300 ns5:EntitiesWithJointControlOrSignificantInfluenceOverReportingEntity 2023-04-01 2024-03-31 01413300 ns5:OtherRelatedPartyRelationshipType1ComponentTotalRelatedParties 2024-04-01 2025-03-31 01413300 ns5:OtherRelatedPartyRelationshipType1ComponentTotalRelatedParties 2023-04-01 2024-03-31 01413300 ns5:OtherRelatedPartyRelationshipType1ComponentTotalRelatedParties 2025-03-31 01413300 ns5:OtherRelatedPartyRelationshipType1ComponentTotalRelatedParties 2024-03-31 01413300 ns5:OtherRelatedPartyRelationshipType2ComponentTotalRelatedParties 2024-04-01 2025-03-31 01413300 ns5:OtherRelatedPartyRelationshipType2ComponentTotalRelatedParties 2023-04-01 2024-03-31 01413300 ns5:OtherRelatedPartyRelationshipType2ComponentTotalRelatedParties 2025-03-31 01413300 ns5:OtherRelatedPartyRelationshipType2ComponentTotalRelatedParties 2024-03-31 01413300 ns5:OtherRelatedParties 2024-04-01 2025-03-31 01413300 ns5:OtherRelatedParties 2023-04-01 2024-03-31 01413300 ns5:OtherRelatedParties 2025-03-31 01413300 ns5:OtherRelatedParties 2024-03-31

REGISTERED NUMBER: 01413300 (England and Wales)

| Strategic Report, Report of the Directors and |

| Financial Statements for the Year Ended 31 March 2025 |

| for |

| Camstar Herbs Limited |

| Camstar Herbs Limited (Registered number: 01413300) |

Contents of the Financial Statements

for the Year Ended 31 March 2025

Page |

| Company Information | 1 |

| Strategic Report | 2 |

| Report of the Directors | 3 |

| Report of the Independent Auditors | 5 |

| Income Statement | 9 |

| Other Comprehensive Income | 10 |

| Balance Sheet | 11 |

| Statement of Changes in Equity | 12 |

| Cash Flow Statement | 13 |

| Notes to the Cash Flow Statement | 14 |

| Notes to the Financial Statements | 16 |

| Camstar Herbs Limited |

Company Information

for the Year Ended 31 March 2025

| DIRECTORS: | Mrs T Dewsbery-Clark

| E J B Starke

| M T Hoxworth

| G Keach

| SECRETARY: | Mrs T Dewsbery-Clark

| REGISTERED OFFICE: | Chestnuts Farm

| Langton Green

| Eye

| Suffolk

| IP23 7HL

| REGISTERED NUMBER: | 01413300 (England and Wales)

| AUDITORS: | Knights Lowe Limited

| Eldo House

| Kempson Way

| Suffolk Business Park

| Bury St Edmunds

| Suffolk

| IP32 7AR

| Camstar Herbs Limited (Registered number: 01413300) |

Strategic Report

for the Year Ended 31 March 2025

The directors present their strategic report for the year ended 31 March 2025.

REVIEW OF BUSINESS

This year has seen challenging operational issues within the company, but it is encouraging to see turnover increase from last year..

The brand new production facility is now fully operational and has resulted in an increase in production capacity, which will allow the company to continue to drive efficiencies and the directors are hopeful for the future.

Key performance indicators

The key performance indicators for Camstar Herbs Ltd are net profit margin and gross profit margin. The company have chosen these to represent the company's performance and position as increasing turnover has been a key objective for the company in recent years. Net profit is a key indicator for the company as it gives a more holistic view of how the company is performing and allows them to review their costs for maximum efficiencies.

The results for the year, as shown on the statement of comprehensive income, shows a gross profit margin of 33.6% (2024: 31.0%) and net profit margin of 11.2% (2024: 8.4%). The net profit increase was caused partly by the decrease in the Bank Base Rate and therefore the decrease in Interest Payable.

Revenue has increased from £23.9m to £27.8m in 2025.

The balance sheet has continued to strengthen, with net assets now standing at £29.2m (2024: £27.1m).

PRINCIPAL RISKS AND UNCERTAINTIES

Due to the high levels of investment, and the requirement to hold high stock levels at various times in the year, cash flow has to be managed very carefully by the company. It is planned that profits expected in the year ended 31 March 2023 will be realised into cash and reduce the reliance on bank debt finance in future years.

ON BEHALF OF THE BOARD:

Mrs T Dewsbery-Clark - Secretary

6 March 2026

| Camstar Herbs Limited (Registered number: 01413300) |

Report of the Directors

for the Year Ended 31 March 2025

The directors present their report with the financial statements of the company for the year ended 31 March 2025.

PRINCIPAL ACTIVITY

The principal activity of the company in the year under review was that of production and sale of herbal products.

DIVIDENDS

Interim dividends totalling £25833.33 per share were paid on the Ordinary "A" £1 shares during the year. No dividends were paid on the Ordinary £1 shares.

The total distribution of dividends for the year ended 31 March 2025 will be £ 750,000 .

DIRECTORS

The directors shown below have held office during the whole of the period from 1 April 2024 to the date of this report.

Mrs T Dewsbery-Clark

E J B Starke

M T Hoxworth

G Keach

STATEMENT OF DIRECTORS' RESPONSIBILITIES

The directors are responsible for preparing the Strategic Report, the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

- | select suitable accounting policies and then apply them consistently;

- | make judgements and accounting estimates that are reasonable and prudent;

- | prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS

So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the company's auditors are unaware, and each director has taken all the steps that he or she ought to have taken as a director in order to make himself or herself aware of any relevant audit information and to establish that the company's auditors are aware of that information.

| Camstar Herbs Limited (Registered number: 01413300) |

Report of the Directors

for the Year Ended 31 March 2025

AUDITORS

The auditors, having expressed their willingness to continue in office, will be deemed reappointed for the financial year in accordance with the section 487(2) of the Companies Act 2006 unless the company receives notice under section 488(1) of the Companies Act 2006.

ON BEHALF OF THE BOARD:

Mrs T Dewsbery-Clark - Secretary

6 March 2026

Report of the Independent Auditors to the Members of

Camstar Herbs Limited

Opinion

We have audited the financial statements of Camstar Herbs Limited (the 'company') for the year ended 31 March 2025 which comprise the Income Statement, Other Comprehensive Income, Balance Sheet, Statement of Changes in Equity, Cash Flow Statement and Notes to the Cash Flow Statement, Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- | give a true and fair view of the state of the company's affairs as at 31 March 2025 and of its profit for the year then ended;

- | have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and

- | have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The directors are responsible for the other information. The other information comprises the information in the Strategic Report and the Report of the Directors, but does not include the financial statements and our Report of the Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- | the information given in the Strategic Report and the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and

- | the Strategic Report and the Report of the Directors have been prepared in accordance with applicable legal requirements.

Report of the Independent Auditors to the Members of

Camstar Herbs Limited

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report or the Report of the Directors.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- | adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or

- | the financial statements are not in agreement with the accounting records and returns; or

- | certain disclosures of directors' remuneration specified by law are not made; or

- | we have not received all the information and explanations we require for our audit.

Responsibilities of directors

As explained more fully in the Statement of Directors' Responsibilities set out on page three, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Report of the Independent Auditors to the Members of

Camstar Herbs Limited

Auditors' responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows:

- the engagement partner ensured that the engagement team collectively had the appropriate competence, capabilities and skills to identify or recognise non-compliance with applicable laws and regulations;

- we identified the laws and regulations applicable to the company through discussions with the director and other management, and from our commercial knowledge and experience of the companies operating sector;

- we focused on specific laws and regulations which we considered may have a direct material effect on the financial statements or the operations of the company, including the Companies Act 2006, taxation legislation, data protection, anti-bribery, employment, environmental and health and safety legislation;

- we assessed the extent of compliance with the laws and regulations identified above through making enquiries of management and inspecting legal correspondence; and

- identified laws and regulations were communicated within the audit team regularly and the team remained alert to instances of non-compliance throughout the audit.

We assessed the susceptibility of the company's financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by:

- making enquiries of management as to where they considered there was susceptibility to fraud, their knowledge of actual, suspected and alleged fraud;

- considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations;

To address the risk of fraud through management bias and override of controls, we:

- performed analytical procedures to identify any unusual or unexpected relationships;

- tested journal entries to identify unusual transactions;

- assessed whether judgements and assumptions made in determining the accounting estimates were indicative of potential bias;

- investigated the rationale behind significant or unusual transactions;

In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:

- agreeing financial statement disclosures to underlying supporting documentation;

- reading the minutes of meetings of those charged with governance;

- enquiring of management as to actual and potential litigation and claims;

- reviewing correspondence with HMRC, relevant regulators including the Environment Agency and the company's legal advisors;

There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the directors and other management and the inspection of regulatory and legal correspondence, if any.

Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Auditors.

Report of the Independent Auditors to the Members of

Camstar Herbs Limited

Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

James Knights BSc FCA (Senior Statutory Auditor)

for and on behalf of Knights Lowe Limited

Eldo House

Kempson Way

Suffolk Business Park

Bury St Edmunds

Suffolk

IP32 7AR

6 March 2026

| Camstar Herbs Limited (Registered number: 01413300) |

Income Statement

for the Year Ended 31 March 2025

| 2025 | 2024 |

| Notes | £ | £ | £ | £ |

TURNOVER | 4 | 27,816,134 |  | 23,970,195 |  |

Cost of sales | 18,472,441 |  | 16,535,311 |  |

GROSS PROFIT | 9,343,693 |  | 7,434,884 |  |

Distribution costs | 1,358,540 |  | 1,198,801 |  |

Administrative expenses | 4,453,586 |  | 4,082,559 |  |

|  |  | 5,812,126 |  |  |  |  | 5,281,360 |  |

3,531,567 |  | 2,153,524 |  |

Other operating income | 550,964 |  | 1,370,151 |  |

OPERATING PROFIT | 6 | 4,082,531 |  | 3,523,675 |  |

Interest receivable and similar income | 32,548 |  | 19,771 |  |

4,115,079 |  | 3,543,446 |  |

Interest payable and similar expenses | 8 | 1,003,003 |  | 1,135,760 |  |

PROFIT BEFORE TAXATION | 3,112,076 |  | 2,407,686 |  |

Tax on profit | 9 | 264,303 |  | 387,606 |  |

PROFIT FOR THE FINANCIAL YEAR | 2,847,773 |  | 2,020,080 |  |

| Camstar Herbs Limited (Registered number: 01413300) |

Other Comprehensive Income

for the Year Ended 31 March 2025

| 2025 |  | 2024

| Notes | £ | £ |

PROFIT FOR THE YEAR | 2,847,773 |  | 2,020,080 |  |

OTHER COMPREHENSIVE INCOME | - |  | - |  |

TOTAL COMPREHENSIVE INCOME FOR THE YEAR | 2,847,773 |  | 2,020,080 |  |

| Camstar Herbs Limited (Registered number: 01413300) |

Balance Sheet

31 March 2025

| 2025 | 2024 |

| Notes | £ | £ | £ | £ |

FIXED ASSETS

Intangible assets | 11 | - |  | 3,000 |  |

Tangible assets | 12 | 25,279,684 |  | 25,090,857 |  |

Investments | 13 | 750 |  | 750 |  |

Investment property | 14 | 1,598,251 |  | 1,598,251 |  |

26,878,685 |  | 26,692,858 |  |

CURRENT ASSETS

Stocks | 15 | 11,113,064 |  | 8,169,958 |  |

Debtors | 16 | 11,314,864 |  | 11,695,675 |  |

Cash at bank | 2,302,348 |  | 644,087 |  |

24,730,276 |  | 20,509,720 |  |

CREDITORS

Amounts falling due within one year | 17 | 11,602,671 |  | 8,020,126 |  |

NET CURRENT ASSETS | 13,127,605 |  | 12,489,594 |  |

TOTAL ASSETS LESS CURRENT LIABILITIES | 40,006,290 |  | 39,182,452 |  |

CREDITORS

Amounts falling due after more than one year | 18 | (8,230,377 | ) | (9,569,131 | ) |

PROVISIONS FOR LIABILITIES | 22 | (2,570,044 | ) | (2,505,225 | ) |

NET ASSETS | 29,205,869 |  | 27,108,096 |  |

CAPITAL AND RESERVES

Called up share capital | 23 | 10,060 |  | 10,060 |  |

Revaluation reserve | 24 | 2,991,418 |  | 2,991,418 |  |

Retained earnings | 24 | 26,204,391 |  | 24,106,618 |  |

SHAREHOLDERS' FUNDS | 29,205,869 |  | 27,108,096 |  |

The financial statements were approved by the Board of Directors and authorised for issue on 6 March 2026 and were signed on its behalf by:

Mrs T Dewsbery-Clark - Director

E J B Starke - Director

| Camstar Herbs Limited (Registered number: 01413300) |

Statement of Changes in Equity

for the Year Ended 31 March 2025

| Called up |

| share |  | Retained |  | Revaluation |  | Total

| capital |  | earnings |  | reserve |  | equity

£ | £ | £ | £ |

Balance at 1 April 2023 | 10,060 |  | 22,836,538 |  | 2,991,418 |  | 25,838,016 |  |

Changes in equity

Dividends | - |  | (750,000 | ) | - |  | (750,000 | ) |

Total comprehensive income | - |  | 2,020,080 |  | - |  | 2,020,080 |  |

Balance at 31 March 2024 | 10,060 |  | 24,106,618 |  | 2,991,418 |  | 27,108,096 |  |

Changes in equity

Dividends | - |  | (750,000 | ) | - |  | (750,000 | ) |

Total comprehensive income | - |  | 2,847,773 |  | - |  | 2,847,773 |  |

Balance at 31 March 2025 | 10,060 |  | 26,204,391 |  | 2,991,418 |  | 29,205,869 |  |

| Camstar Herbs Limited (Registered number: 01413300) |

Cash Flow Statement

for the Year Ended 31 March 2025

| 2025 |  | 2024

| Notes | £ | £ |

Cash flows from operating activities

Cash generated from operations | 1 | 3,828,529 |  | 2,636,517 |  |

Interest paid | (953,778 | ) | (1,073,927 | ) |

Interest element of hire purchase payments paid | (49,225 | ) | (61,833 | ) |

Tax paid | (32,549 | ) | (668,349 | ) |

Net cash from operating activities | 2,792,977 |  | 832,408 |  |

Cash flows from investing activities

Purchase of tangible fixed assets | (768,001 | ) | (3,173,296 | ) |

Sale of tangible fixed assets | 13,749 |  | 499 |  |

Interest received | 32,548 |  | 19,771 |  |

Net cash from investing activities | (721,704 | ) | (3,153,026 | ) |

Cash flows from financing activities

New hire purchase in year | 69,735 |  | 794,750 |  |

New loans | - |  | 10,500,000 |  |

Movement in loans to group companies | (106,246 | ) | 377,356 |  |

HP capital repaid in year | (316,831 | ) | (430,803 | ) |

Amount introduced by directors | 784,862 |  | 981,103 |  |

Amount withdrawn by directors | (846,549 | ) | - |  |

Loan capital repaid in year | (1,128,823 | ) | (8,218,681 | ) |

Invoice finance loan movement | 63,687 |  | (1,622,011 | ) |

Equity dividends paid | (750,000 | ) | (750,000 | ) |

Net cash from financing activities | (2,230,165 | ) | 1,631,714 |  |

Decrease in cash and cash equivalents | (158,892 | ) | (688,904 | ) |

Cash and cash equivalents at beginning of year | 2 | (629,405 | ) | 59,499 |  |

Cash and cash equivalents at end of year | 2 | (788,297 | ) | (629,405 | ) |

| Camstar Herbs Limited (Registered number: 01413300) |

Notes to the Cash Flow Statement

for the Year Ended 31 March 2025

1. | RECONCILIATION OF PROFIT BEFORE TAXATION TO CASH GENERATED FROM OPERATIONS

| 2025 |  | 2024

£ | £ |

| Profit before taxation | 3,112,076 |  | 2,407,686 |  |

| Depreciation charges | 561,220 |  | 512,699 |  |

| Loss on disposal of fixed assets | 7,204 |  | 14,602 |  |

| Finance costs | 1,003,003 |  | 1,135,760 |  |

| Finance income | (32,548 | ) | (19,771 | ) |

4,650,955 |  | 4,050,976 |  |

| Increase in stocks | (2,943,106 | ) | (43,227 | ) |

| Decrease/(increase) in trade and other debtors | 386,568 |  | (897,194 | ) |

| Increase/(decrease) in trade and other creditors | 1,734,112 |  | (474,038 | ) |

| Cash generated from operations | 3,828,529 |  | 2,636,517 |  |

2. | CASH AND CASH EQUIVALENTS

| The amounts disclosed on the Cash Flow Statement in respect of cash and cash equivalents are in respect of these Balance Sheet amounts:

| Year ended 31 March 2025

| 31.3.25 |  | 1.4.24

£ | £ |

| Cash and cash equivalents | 2,302,348 |  | 644,087 |  |

| Bank overdrafts | (3,090,645 | ) | (1,273,492 | ) |

(788,297 | ) | (629,405 | ) |

| Year ended 31 March 2024

| 31.3.24 |  | 1.4.23

£ | £ |

| Cash and cash equivalents | 644,087 |  | 2,138,220 |  |

| Bank overdrafts | (1,273,492 | ) | (2,078,721 | ) |

(629,405 | ) | 59,499 |  |

| Camstar Herbs Limited (Registered number: 01413300) |

Notes to the Cash Flow Statement

for the Year Ended 31 March 2025

3. | ANALYSIS OF CHANGES IN NET DEBT

| At 1.4.24 | Cash flow | At 31.3.25

£ | £ | £ |

| Net cash |

| Cash at bank | 644,087 |  | 1,658,261 |  | 2,302,348 |  |

| Bank overdrafts | (1,273,492 | ) | (1,817,153 | ) | (3,090,645 | ) |

(629,405 | ) | (158,892 | ) | (788,297 | ) |

| Debt

| Finance leases | (835,057 | ) | 247,096 |  | (587,961 | ) |

| Debts falling due within 1 year | (4,257,498 | ) | (172,616 | ) | (4,430,114 | ) |

| Debts falling due after 1 year | (9,049,129 | ) | 1,237,753 |  | (7,811,376 | ) |

(14,141,684 | ) | 1,312,233 |  | (12,829,451 | ) |

| Total | (14,771,089 | ) | 1,153,341 |  | (13,617,748 | ) |

| Camstar Herbs Limited (Registered number: 01413300) |

Notes to the Financial Statements

for the Year Ended 31 March 2025

1. | STATUTORY INFORMATION

| Camstar Herbs Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

| The presentation currency of the financial statements is the Pound Sterling (£).

2. | STATEMENT OF COMPLIANCE

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

3. | ACCOUNTING POLICIES

| Basis of preparing the financial statements

| The financial statements have been prepared under the historical cost convention as modified by the revaluation of certain assets.

| Going concern

| The effects of the global economic situation have been carefully considered when preparing these financial statements. These financial statements continue to be prepared on a going concern basis as the directors are confident, that with the continued support of the bank financing in place that the company is in a strong financial position to continue to trade going forward.

| Preparation of consolidated financial statements

| The financial statements contain information about Camstar Herbs Limited as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under Section 400 of the Companies Act 2006 from the requirements to prepare consolidated financial statements as it and its subsidiary undertaking are included by full consolidation in the consolidated financial statements of its parent, Starke Industries Limited, Chestnuts Farm, Langton Green, Eye, Suffolk, IP23 7HL.

| Turnover

| Turnover represents net invoiced sales of goods and services excluding value added tax.

| Goodwill

| Goodwill, being the amount paid in connection with the acquisition of a business in 2016, is being amortised evenly over its estimated useful life of ten years.

| Intangible assets

| Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

| Camstar Herbs Limited (Registered number: 01413300) |

Notes to the Financial Statements - continued

for the Year Ended 31 March 2025

3. | ACCOUNTING POLICIES - continued

| Tangible fixed assets

| Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life or, if held under a finance lease, over the lease term, whichever is the shorter.

| Agricultural land | - | no depreciation is provided on land

| Land & buildings | - | 2% straight line on buildings and no depreciation is provided on land

| Plant & equipment | - | 25% on reducing balance and 10% on reducing balance

| Fixtures & fittings | - | 25% on reducing balance

| Motor vehicles | - | 25% on reducing balance

| The measurement basis for freehold land and buildings is at fair value, on a revaluation basis.

| Plant, machinery and all other tangible fixed assets are held at historic cost, less accumulated depreciation.The directors estimate residual values on an asset by asset basis and apply depreciation accordingly.

| Revaluation surplus is shown through other comprehensive income and is shown in a seperate revaluation reserve within equity as is non-distributable.

| During the year a full review has been made of freehold land & buildings and the directors have considered the valuation for each individual asset and that the revaluation method is the most appropriate recognition method going forward. Therefore these are recognised at current fair value.

| The directors consider freehold land and buildings on a group basis for impairment, and should the recoverable amount be below valuation or cost an impairment review is carried out and recognised as required.The position will be reviewed annually.

| Investment property

| Investment properties are held for long-term investment. Investment properties are initially recognised at cost which includes purchase cost and any directly attributable expenditure. Investment properties whose fair value can be measured reliably are measured at fair value. The surplus or deficit on revaluation is recognised in the revaluation reserve within equity as is non-distributable unless a deficit below original cost, or its reversal, on an individual investment property is expected to be permanent, in which case it is recognised in the profit and loss account for the year.

| Stocks

| Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

| Cost valuation of manufactured and processed product includes all direct expenditure and an appropriate proportion of fixed and variable overhead. This method provides an appropriate cost value for this stock.

| Stock is then regularly reviewed for impairment and adjusted as necessary.

| Camstar Herbs Limited (Registered number: 01413300) |

Notes to the Financial Statements - continued

for the Year Ended 31 March 2025

3. | ACCOUNTING POLICIES - continued

| Financial instruments

| The company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other accounts receivable and payable, and loans from banks or other related parties.

| Debt instruments, like loans and other accounts receivable and payable, are initially measured at present value of the future payments and subsequently at amortised cost using the effective interest method. Debt instruments that are payable or receivable within one year, typically trade payables or receivables, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration, expected to be paid or received. However if the arrangements of a short-term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms or financed at a rate of interest that is not a market rate or in case of an outright short-term loan not at market rate, the financial asset or liability is measured, initially and subsequently, at the present value of the future payment discounted at a market rate of interest for a similar debt instrument.

| Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Statement of Comprehensive Income.

| For financial assets measured at amortised cost, the impairment loss is measured as the difference between an asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If a financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

| For financial assets measured at cost less impairment, the impairment loss is measured as the difference between an asset's carrying amount and best estimate, which is an approximation of the amount that the company would receive for the asset if it were to be sold at the balance sheet date.

| Financial assets and liabilities are offset and the net amount reported in the Balance sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

| Taxation

| Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

| Current or deferred taxation assets and liabilities are not discounted.

| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

| Deferred tax

| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

| Camstar Herbs Limited (Registered number: 01413300) |

Notes to the Financial Statements - continued

for the Year Ended 31 March 2025

3. | ACCOUNTING POLICIES - continued

| Foreign currencies

| Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

| Hire purchase and leasing commitments

| Assets obtained under hire purchase contracts or finance leases are capitalised in the balance sheet. Those held under hire purchase contracts are depreciated over their estimated useful lives. Those held under finance leases are depreciated over their estimated useful lives or the lease term, whichever is the shorter.

| The interest element of these obligations is charged to profit or loss over the relevant period. The capital element of the future payments is treated as a liability.

| Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

| Pension costs and other post-retirement benefits

| The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

| Impairment

| At each reporting date, goodwill and other fixed assets, including tangible fixed assets and investments but excluding investment properties, are assessed to determine whether there is an indication that the carrying amount of an asset may be more than its recoverable amount and that the asset should be impaired. If there is an indication of possible impairment, the recoverable amount of an asset, which is the higher of its value in use and its net realisable value, is estimated and compared with its carrying amount. If the recoverable amount is lower, the carrying amount of the asset is written down to its estimated recoverable amount and an impairment loss is recognised in profit and loss.

| Investments in subsidiaries

| Investments in subsidiaries are accounted for at cost less impairment.

| Revaluation reserve

| It is the company's policy to transfer to the revaluation reserve all non-distributable fair value movements recognised in the profit and loss account together with deferred taxation thereon.

4. | TURNOVER

| The turnover and profit before taxation are attributable to the one principal activity of the company.

| An analysis of turnover by geographical market is given below:

| 2025 |  | 2024

£ | £ |

| United Kingdom | 14,939,207 |  | 12,938,454 |  |

| Outside UK Sales | 12,876,927 |  | 11,031,741 |  |

27,816,134 |  | 23,970,195 |  |

| The percentage of turnover attributable to markets outside the UK is 46.3% (2024: 46%).

| Camstar Herbs Limited (Registered number: 01413300) |

Notes to the Financial Statements - continued

for the Year Ended 31 March 2025

5. | EMPLOYEES AND DIRECTORS

| 2025 |  | 2024

£ | £ |

| Wages and salaries | 4,383,769 |  | 4,136,435 |  |

| Social security costs | 167,965 |  | 157,884 |  |

| Other pension costs | 36,641 |  | 32,865 |  |

4,588,375 |  | 4,327,184 |  |

| The average number of employees during the year was as follows:

| 2025 |  | 2024

| Directors | 4 |  | 4 |  |

| Other staff | 139 |  | 83 |  |

143 |  | 87 |  |

| 2025 |  | 2024

£ | £ |

| Directors' remuneration | 1,027,690 |  | 1,052,008 |  |

| The number of directors to whom retirement benefits were accruing was as follows:

| Money purchase schemes | 1 |  | 1 |  |

| Information regarding the highest paid director is as follows:

| 2025 |  | 2024

£ | £ |

| Emoluments etc | 815,783 |  | 763,282 |  |

6. | OPERATING PROFIT

| The operating profit is stated after charging:

| 2025 |  | 2024

£ | £ |

| Repairs & renewals | 347,070 |  | 391,267 |  |

| Other operating leases | 91,407 |  | 88,116 |  |

| Depreciation - owned assets | 458,704 |  | 466,561 |  |

| Depreciation - assets on hire purchase contracts | 99,517 |  | 43,139 |  |

| Loss on disposal of fixed assets | 7,204 |  | 14,602 |  |

| Goodwill amortisation | 3,000 |  | 3,000 |  |

| Auditors' remuneration | 7,000 |  | 6,500 |  |

| Camstar Herbs Limited (Registered number: 01413300) |

Notes to the Financial Statements - continued

for the Year Ended 31 March 2025

7. | EXCEPTIONAL ITEMS

| 2025 |  | 2024

£ | £ |

| Exceptional Income | 209,397 |  | 1,087,239 |  |

| Exceptional Expenses | (156,583 | ) | (502,262 | ) |

52,814 |  | 584,977 |  |

| 2025: During the year, the company recognised exceptional income of £209,397 in relation to insurance compen sation received for business interruption. This amount includes coverage of associated legal and profes sional costs incurred in connection with the matter.

| Exceptional costs of £156,583 were also incurred during the year, relating to legal and professional fees associated with historic insurance claims arising from a fire incident in 2021. These costs were incurred in assessing whether the incident was managed appropriately by the company’s insurance broker and whether the level of insurance cover in place at the time was adequate.

| 2024: In July 2023, the company had an interruption of production.

| The exceptional income above of £906,614 relates to insurance compensation received for business interruption in relation to the exceptional expenses detailed below shown in the profit and loss account.

| The exceptional expenses above of £502,262 relates compensation paid to the parsley farmers.

8. | INTEREST PAYABLE AND SIMILAR EXPENSES |

| 2025 |  | 2024

£ | £ |

| Bank interest | 51,559 |  | 100,917 |  |

| Bank loan interest | 687,419 |  | 722,277 |  |

| Bank charges | 15,971 |  | 13,913 |  |

| Foreign exchange differences | (50,194 | ) | (66,583 | ) |

| Loan Arrangement Fees | - |  | 68,750 |  |

| Invoice financing interest | 227,573 |  | 199,025 |  |

| Invoice financing charge | 21,450 |  | 22,172 |  |

| PAYE Interest | - |  | 721 |  |

| Other interest paid | - |  | 12,735 |  |

| Hire purchase interest | 49,225 |  | 61,833 |  |

1,003,003 |  | 1,135,760 |  |

| Camstar Herbs Limited (Registered number: 01413300) |

Notes to the Financial Statements - continued

for the Year Ended 31 March 2025

9. | TAXATION

| Analysis of the tax charge

| The tax charge on the profit for the year was as follows:

| 2025 |  | 2024

£ | £ |

| Current tax:

| UK corporation tax | 500,268 |  | 476,935 |  |

| Adjustment re: previous years | (300,784 | ) | (86,171 | ) |

| Total current tax | 199,484 |  | 390,764 |  |

| Deferred tax | 64,819 |  | (3,158 | ) |

| Tax on profit | 264,303 |  | 387,606 |  |

| UK corporation tax has been charged at 25% .

| Reconciliation of total tax charge included in profit and loss

| The tax assessed for the year is lower than the standard rate of corporation tax in the UK. The difference is explained below:

| 2025 |  | 2024

£ | £ |

| Profit before tax | 3,112,076 |  | 2,407,686 |  |

| Profit multiplied by the standard rate of corporation tax in the UK of 25% (2024 - 25%) | 778,019 |  | 601,922 |  |

| Effects of:

| Expenses not deductible for tax purposes | 3,189 |  | 8,869 |  |

| Capital allowances in excess of depreciation | (58,997 | ) | - |  |

| Deferred tax adjustment | 64,819 |  | - |  |

| properties not taxable |

| Enhanced R&D tax relief | (149,608 | ) | (153,671 | ) |

| Prior year tax adjustment | (300,784 | ) | (69,514 | ) |

| Group relief | (72,335 | ) | - |  |

| Total tax charge | 264,303 |  | 387,606 |  |

10. | DIVIDENDS

| 2025 |  | 2024

£ | £ |

| Ordinary "A" shares of £1 each |

| Interim | 750,000 |  | 750,000 |  |

| Camstar Herbs Limited (Registered number: 01413300) |

Notes to the Financial Statements - continued

for the Year Ended 31 March 2025

11. | INTANGIBLE FIXED ASSETS

| Goodwill

£ |

| COST

| At 1 April 2024

| and 31 March 2025 | 30,000 |  |

| AMORTISATION

| At 1 April 2024 | 27,000 |  |

| Amortisation for year | 3,000 |  |

| At 31 March 2025 | 30,000 |  |

| NET BOOK VALUE

| At 31 March 2025 | - |  |

| At 31 March 2024 | 3,000 |  |

12. | TANGIBLE FIXED ASSETS

| Agricultural |  | Land & |  | Plant &

| land |  | buildings |  | equipment

£ | £ | £ |

| COST OR VALUATION

| At 1 April 2024 | 748,205 |  | 18,301,721 |  | 7,874,572 |  |

| Additions | - |  | 90,794 |  | 590,551 |  |

| Disposals | - |  | - |  | (52,609 | ) |

| At 31 March 2025 | 748,205 |  | 18,392,515 |  | 8,412,514 |  |

| DEPRECIATION

| At 1 April 2024 | - |  | - |  | 2,034,507 |  |

| Charge for year | - |  | - |  | 501,638 |  |

| Eliminated on disposal | - |  | - |  | (46,533 | ) |

| At 31 March 2025 | - |  | - |  | 2,489,612 |  |

| NET BOOK VALUE

| At 31 March 2025 | 748,205 |  | 18,392,515 |  | 5,922,902 |  |

| At 31 March 2024 | 748,205 |  | 18,301,721 |  | 5,840,065 |  |

| Camstar Herbs Limited (Registered number: 01413300) |

Notes to the Financial Statements - continued

for the Year Ended 31 March 2025

12. | TANGIBLE FIXED ASSETS - continued

| Fixtures |  | Motor |

| & fittings |  | vehicles |  | Totals

£ | £ | £ |

| COST OR VALUATION

| At 1 April 2024 | 401,310 |  | 80,140 |  | 27,405,948 |  |

| Additions | 16,921 |  | 69,735 |  | 768,001 |  |

| Disposals | (35,505 | ) | (40,000 | ) | (128,114 | ) |

| At 31 March 2025 | 382,726 |  | 109,875 |  | 28,045,835 |  |

| DEPRECIATION

| At 1 April 2024 | 230,649 |  | 49,935 |  | 2,315,091 |  |

| Charge for year | 45,333 |  | 11,250 |  | 558,221 |  |

| Eliminated on disposal | (33,152 | ) | (27,476 | ) | (107,161 | ) |

| At 31 March 2025 | 242,830 |  | 33,709 |  | 2,766,151 |  |

| NET BOOK VALUE

| At 31 March 2025 | 139,896 |  | 76,166 |  | 25,279,684 |  |

| At 31 March 2024 | 170,661 |  | 30,205 |  | 25,090,857 |  |

| Tangible fixed assets with a carrying value of £18,392,515 (2024: £18,301,721) are pledged as security for the company's bank loans.

| Cost or valuation at 31 March 2025 is represented by:

| Agricultural |  | Land & |  | Plant &

| land |  | buildings |  | equipment

£ | £ | £ |

| Valuation in 2022 | - |  | 4,086,312 |  | - |  |

| Valuation in 2023 | - |  | (465,419 | ) | - |  |

| Cost | 748,205 |  | 14,771,622 |  | 8,412,514 |  |

748,205 |  | 18,392,515 |  | 8,412,514 |  |

| Fixtures |  | Motor |

| & fittings |  | vehicles |  | Totals

£ | £ | £ |

| Valuation in 2022 | - |  | - |  | 4,086,312 |  |

| Valuation in 2023 | - |  | - |  | (465,419 | ) |

| Cost | 382,726 |  | 109,875 |  | 24,424,942 |  |

382,726 |  | 109,875 |  | 28,045,835 |  |

| Camstar Herbs Limited (Registered number: 01413300) |

Notes to the Financial Statements - continued

for the Year Ended 31 March 2025

12. | TANGIBLE FIXED ASSETS - continued

| Freehold land and buildings with a cost of £11,020,902 was revalued by the directors at 31 March 2023. The directors have concluded this valuation based on the formal valuation completed by Lambert Smith Hampton on 28 March 2023.

| The directors have not revalued the new dryer building with cost base of £1,531,048. The directors consider the current valuation of this asset to be inline with the original cost at £1,531,048 as this is a recent addition and the directors basis is its value in use rather than that Lambert Smith Hampton valuation on a square foot base of £685,000.

| The director consider the revaluation completed in March 2023 to be the current valuation and additions have been included on a cost basis.

| Fixed assets, included in the above, which are held under hire purchase contracts are as follows:

| Land & |  | Plant & |  | Motor |

| buildings |  | equipment |  | vehicles |  | Totals

£ | £ | £ | £ |

| COST OR VALUATION

| At 1 April 2024 | 589,500 |  | 982,026 |  | 58,000 |  | 1,629,526 |  |

| Additions | - |  | - |  | 69,735 |  | 69,735 |  |

| Disposals | - |  | - |  | (40,000 | ) | (40,000 | ) |

| Transfer to ownership | (589,500 | ) | - |  | (18,000 | ) | (607,500 | ) |

| At 31 March 2025 | - |  | 982,026 |  | 69,735 |  | 1,051,761 |  |

| DEPRECIATION

| At 1 April 2024 | - |  | 76,959 |  | 36,839 |  | 113,798 |  |

| Charge for year | - |  | 90,528 |  | 8,989 |  | 99,517 |  |

| Eliminated on disposal | - |  | - |  | (27,476 | ) | (27,476 | ) |

| Transfer to ownership | - |  | - |  | (13,995 | ) | (13,995 | ) |

| At 31 March 2025 | - |  | 167,487 |  | 4,357 |  | 171,844 |  |

| NET BOOK VALUE

| At 31 March 2025 | - |  | 814,539 |  | 65,378 |  | 879,917 |  |

| At 31 March 2024 | 589,500 |  | 905,067 |  | 21,161 |  | 1,515,728 |  |

13. | FIXED ASSET INVESTMENTS

| Unlisted

| investments

£ |

| COST

| At 1 April 2024

| and 31 March 2025 | 750 |  |

| NET BOOK VALUE

| At 31 March 2025 | 750 |  |

| At 31 March 2024 | 750 |  |

| Camstar Herbs Limited (Registered number: 01413300) |

Notes to the Financial Statements - continued

for the Year Ended 31 March 2025

13. | FIXED ASSET INVESTMENTS - continued

| The company's investments at the Balance Sheet date in the share capital of companies include the following:

| Camstar Ingredients Limited

| Registered office: Chestnuts Farm, Langton Green, Eye, Suffolk, IP23 7HL

| Nature of business: Production and sale of spice blends and sauces

| %

| Class of shares: | holding |

| Ordinary | 75.76 |

14. | INVESTMENT PROPERTY

| Total

£ |

| FAIR VALUE

| At 1 April 2024

| and 31 March 2025 | 1,598,251 |  |

| NET BOOK VALUE

| At 31 March 2025 | 1,598,251 |  |

| At 31 March 2024 | 1,598,251 |  |

| The fair value of the investment properties has been determined by a valuation completed on 28 March 2023 by Lambert Smith Hampton and the directors consider this to be the valuation of the investment properties at 31 March 2024 with the exception of one investment property.

| The directors have not revalued The Barn with cost base of £803,250. The directors consider the current valuation of this asset to be inline with the original cost at £803,250 as this is a recent addition and the valuation completed by Lambert Smith Hampton did not include all elements of this purchase as there were several properties as part of this transaction.

| The directors consider these valuations to be the current fair value on an open market basis.

| Fair value at 31 March 2025 is represented by:

£ |

| Valuation in 2018 | 164,289 |  |

| Valuation in 2023 | 87,313 |  |

| Cost | 1,346,649 |  |

1,598,251 |  |

| If investment property had not been revalued it would have been included at the following historical cost:

2025 | 2024 |

£ | £ |

| Cost | 1,346,649 |  | 1,346,649 |  |

| Camstar Herbs Limited (Registered number: 01413300) |

Notes to the Financial Statements - continued

for the Year Ended 31 March 2025

15. | STOCKS

2025 | 2024 |

£ | £ |

| Stocks | 11,113,064 |  | 8,169,958 |  |

| Included in the stock figures above is £139,315 which relates to the value of the growing Camomile crop in the ground at the year end (2024: £134,518).

16. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Trade debtors | 4,841,816 |  | 4,456,399 |  |

| Amounts owed by group undertakings | 4,181,818 |  | 4,075,572 |  |

| Other debtors | 329,526 |  | 187,931 |  |

| Directors' loan accounts | 840,007 |  | 778,320 |  |

| Corporation tax | - |  | 290,709 |  |

| Prepayments & accrued income | 1,121,697 |  | 1,906,744 |  |

11,314,864 |  | 11,695,675 |  |

17. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Bank loans and overdrafts (see note 19) | 4,135,682 |  | 2,209,599 |  |

| Other loans (see note 19) | 3,385,077 |  | 3,321,391 |  |

| Hire purchase contracts (see note 20) | 168,960 |  | 315,055 |  |

| Trade creditors | 3,466,158 |  | 1,879,448 |  |

| Corporation tax | 4,759 |  | - |  |

| Other taxes & social security | 108,261 |  | 102,004 |  |

| Other creditors | 7,736 |  | 5,790 |  |

| Accruals & deferred income | 326,038 |  | 186,839 |  |

11,602,671 |  | 8,020,126 |  |

18. | CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR |

2025 | 2024 |

£ | £ |

| Bank loans (see note 19) | 7,811,376 |  | 9,049,129 |  |

| Hire purchase contracts (see note 20) | 419,001 |  | 520,002 |  |

8,230,377 |  | 9,569,131 |  |

| Camstar Herbs Limited (Registered number: 01413300) |

Notes to the Financial Statements - continued

for the Year Ended 31 March 2025

19. | LOANS

| An analysis of the maturity of loans is given below:

2025 | 2024 |

£ | £ |

| Amounts falling due within one year or on demand:

| Bank overdrafts | 3,090,645 |  | 1,273,492 |  |

| Bank loans | 1,045,037 |  | 936,107 |  |

| Other loans | 3,385,077 |  | 3,321,391 |  |

7,520,759 |  | 5,530,990 |  |

| Amounts falling due between one and two years:

| Bank loans | 1,126,348 |  | 1,000,614 |  |

| Amounts falling due between two and five years:

| Bank loans | 6,685,028 |  | 8,048,515 |  |

20. | LEASING AGREEMENTS

| Minimum lease payments fall due as follows:

| Hire purchase |

| contracts |

2025 | 2024 |

£ | £ |

| Net obligations repayable:

| Within one year | 168,960 |  | 315,055 |  |

| Between one and five years | 419,001 |  | 520,002 |  |

587,961 |  | 835,057 |  |

| Non-cancellable |

| operating leases |

2025 | 2024 |

£ | £ |

| Within one year | 30,780 |  | 53,403 |  |

| Between one and five years | 75,038 |  | 100,358 |  |

| In more than five years | 22,295 |  | 27,756 |  |

128,113 |  | 181,517 |  |

| Camstar Herbs Limited (Registered number: 01413300) |

Notes to the Financial Statements - continued

for the Year Ended 31 March 2025

21. | SECURED DEBTS

| The following secured debts are included within creditors:

2025 | 2024 |

£ | £ |

| Bank overdrafts | 3,090,645 |  | 1,273,492 |  |

| Bank loans | 8,856,413 |  | 9,985,236 |  |

| Other loans | 3,385,077 |  | 3,321,391 |  |

| Hire purchase contracts | 587,961 |  | 835,057 |  |

15,920,096 |  | 15,415,176 |  |

| The bank loan is secured by a first charge over all of the company's properties, land and associated assets.

| Other loans are secured specifically against inventory and the company's trade debtors.

| Hire purchase liabilities are secured over the assets financed.

22. | PROVISIONS FOR LIABILITIES

2025 | 2024 |

£ | £ |

| Deferred tax

| Accelerated capital allowances | 1,792,900 |  | 1,728,081 |  |

| Deferred tax on revaluation | 777,144 |  | 777,144 |  |

2,570,044 |  | 2,505,225 |  |

| Deferred |

| tax |

£ |

| Balance at 1 April 2024 | 2,505,225 |  |

| Provided during year | 64,819 |  |

| Balance at 31 March 2025 | 2,570,044 |  |

23. | CALLED UP SHARE CAPITAL

| Allotted, issued and fully paid:

| Number: | Class: | Nominal | 2025 | 2024 |

| value: | £ | £ |

| 60 | Ordinary "A" | £1 | 60 |  | 60 |  |

| Allotted and issued:

| Number: | Class: | Nominal | 2025 | 2024 |

| value: | £ | £ |

| 10,000 | Ordinary | £1 | 10,000 |  | 10,000 |  |

| Camstar Herbs Limited (Registered number: 01413300) |

Notes to the Financial Statements - continued

for the Year Ended 31 March 2025

24. | RESERVES

| Retained |  | Revaluation |

| earnings |  | reserve |  | Totals

£ | £ | £ |

| At 1 April 2024 | 24,106,618 |  | 2,991,418 |  | 27,098,036 |  |

| Profit for the year | 2,847,773 |  | - |  | 2,847,773 |  |

| Dividends | (750,000 | ) | - |  | (750,000 | ) |

| At 31 March 2025 | 26,204,391 |  | 2,991,418 |  | 29,195,809 |  |

25. | ULTIMATE PARENT COMPANY

| Starke Industries Limited is regarded by the directors as being the company's ultimate parent company.

| Registered Office : Chestnuts Farm, Langton Green, Eye, Suffolk, IP23 7HL

26. | CAPITAL COMMITMENTS

2025 | 2024 |

£ | £ |

| Contracted but not provided for in the

| financial statements | 44,155 |  | 230,073 |  |

27. | DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

| The following advances and credits to a director subsisted during the years ended 31 March 2025 and 31 March 2024:

2025 | 2024 |

£ | £ |

| E J B Starke

| Balance outstanding at start of year | 778,320 |  | 1,759,423 |  |

| Amounts advanced | 846,549 |  | - |  |

| Amounts repaid | (784,862 | ) | (981,103 | ) |

| Amounts written off | - |  | - |  |

| Amounts waived | - |  | - |  |

| Balance outstanding at end of year | 840,007 |  | 778,320 |  |

| Interest was charged by the company on advances made to the director at a rate of 2.25% (2024 - 2.25%).

28. | RELATED PARTY DISCLOSURES

| The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

| Entities with control, joint control or significant influence over the entity

2025 | 2024 |

£ | £ |

| Purchases | 84,000 |  | 2,034,000 |  |

| Camstar Herbs Limited (Registered number: 01413300) |

Notes to the Financial Statements - continued

for the Year Ended 31 March 2025

28. | RELATED PARTY DISCLOSURES - continued

| Transactions with subsidiary company

2025 | 2024 |

£ | £ |

| Sales | 1,730,459 |  | 1,505,570 |  |

| Purchases | 272,655 |  | 232,792 |  |

| Amount due from related party | 291,538 |  | 185,292 |  |

| Key Management

2025 | 2024 |

£ | £ |

| Purchases | 3,122 |  | - |  |

| Amount due from related party | 840,007 |  | 778,320 |  |

| Amount due to related party | 267 |  | - |  |

| Other related parties

2025 | 2024 |

£ | £ |

| Sales | 1,000 |  | 1,000 |  |

| Purchases | 1,556 |  | 1,436 |  |

| Amount due from related party | 202 |  | 568 |  |

29. | ULTIMATE CONTROLLING PARTY

| The controlling party is E J B Starke.

| Control is achieved by virtue of a controlling stake in the parent company, Starke Industries Limited.